Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

9.36
+1.0712.91%
Post-market: 9.390.0280+0.30%19:59 EDT
Volume:12.04M
Turnover:110.40M
Market Cap:544.18M
PE:-3.80
High:9.88
Open:8.29
Low:8.05
Close:8.29
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:0.96
T/O Rate:26.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.21
PE(LYR):-4.14

Loading ...

Capricor Therapeutics Raised to Overweight from Neutral by Cantor Fitzgerald

Dow Jones
·
Aug 14

Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why

Benzinga Earnings
·
Aug 14

Capricor Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Capricor Therapeutics Q2 EPS $(0.70) Misses $(0.58) Estimate

Benzinga Earnings
·
Aug 14

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 14

U.S. Earnings Preview: After Market Close Aug. 13

Dow Jones
·
Aug 14

Capricor Therapeutics Lawsuit Focuses on Deramiocel Disclosures After CAPR Stock Drops

TIPRANKS
·
Aug 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 13

Capricor Therapeutics, Inc. Expected to Post a Loss of 59 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Capricor Therapeutics Updates Financial Calendar with Q2 Results Release, Conference Call and Webcast Scheduled

Reuters
·
Aug 10

Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13

THOMSON REUTERS
·
Aug 10

OTLK, HBAN, CORT, CAPR, GOSS Trending With Analysts

TIPRANKS
·
Aug 01

B. Riley Adjusts Capricor Therapeutics Price Target to $5 From $10, Maintains Neutral Rating

MT Newswires Live
·
Jul 31

Health ROUNDS-Experimental Drug Helps Advanced Cancer Patients Avoid Bladder Removal Surgery

Reuters
·
Jul 31

Capricor Therapeutics downgraded to Hold from Buy at JonesResearch

TIPRANKS
·
Jul 31

Health Rounds: Experimental Cell Therapy Slows Heart Failure Progression in Duchenne Muscular Dystrophy

Reuters
·
Jul 31

U.S. Stocks on the MOVE-Mastercard, Starbucks, Meta

Reuters
·
Jul 30

Capricor Therapeutics Hit 52-Week Low on Negative FDA Panel Vote

Dow Jones
·
Jul 30

Capricor: FDA committee voted evidence did not support Deramiocel effectiveness

TIPRANKS
·
Jul 30

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

THOMSON REUTERS
·
Jul 30